CHAMPIONS ONCOLOGY, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$195.00 thousand for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-07-27
- CHAMPIONS ONCOLOGY, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2026 was -$195.00K, a 120.06% decline from fiscal 2025.
- CHAMPIONS ONCOLOGY, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was $972.00K.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2026-04-30 | -$195.00K 10-K · filed 2026-07-27 |
| 2025-04-30 | $972.00K 10-K · filed 2026-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |